Platelet Function Decreases with Increasing Severity of Liver Cirrhosis and Portal Hypertension—A Prospective Study

BACKGROUND AND AIMS  Cirrhotic patients display an increased risk for both bleeding and thrombosis. We investigated platelet activation across Child-Pugh stages (CPSs) and portal hypertension (PH) severity. METHODS  A total of 110 cirrhotic patients were prospectively included. CPS and hepatic venous pressure gradient (HVPG) were determined. Platelet surface expression of P-selectin and activated glycoprotein (GP) IIb/IIIa were measured by flow cytometry before/after stimulation with protease-activated receptor (PAR)-1 (thrombin receptor activating peptide, TRAP) and PAR-4 (AYPGKF) agonists, epinephrine, and lipopolysaccharide (LPS). RESULTS  Platelet count was similar across CPS but lower with increasing PH severity. Expression of P-selectin and activated GPIIb/IIIa in response to TRAP and AYPGKF was significantly reduced in platelets of CPS-B/C versus CPS-A patients (all p < 0.05). Platelet P-selectin expression upon epinephrine and LPS stimulation was reduced in CPS-C patients, while activated GPIIb/IIIa in response to these agonists was lower in CPS-B/C (all p < 0.05). Regarding PH severity, P-selectin and activated GPIIb/IIIa in response to AYPGKF were lower in HVPG ≥20 mmHg patients (both p < 0.001 vs. HVPG < 10 mmHg). Similarly, activated GPIIb/IIIa was lower in HVPG ≥20 mmHg patients after TRAP stimulation (p < 0.01 vs. HVPG < 10 mmHg). The lower platelet surface expression of P-selectin and activated GPIIb/IIIa upon stimulation of thrombin receptors (PAR-1/PAR-4) in CPS-B/C and HVPG ≥20 mmHg patients was paralleled by reduced antithrombin-III levels in those patients (all p < 0.05). Overall, PAR-1- and PAR-4-mediated platelet activation correlated with antithrombin-III levels (p < 0.001). CONCLUSION  Platelet responsiveness decreases with increasing severity of liver cirrhosis and PH but is potentially counterbalanced by lower antithrombin-III levels.

[1]  S. Caldwell,et al.  Haemostatic alterations and management of haemostasis in patients with cirrhosis. , 2022, Journal of hepatology.

[2]  F. Farinati,et al.  Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. , 2022, Journal of hepatology.

[3]  P. Schwabl,et al.  Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis , 2022, Platelets.

[4]  M. Trauner,et al.  Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. , 2020, Journal of visualized experiments : JoVE.

[5]  A. de Gottardi,et al.  The gut-liver axis in liver disease: pathophysiological basis for therapy. , 2020, Journal of hepatology.

[6]  L. Alberio,et al.  Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis , 2020, Hepatology.

[7]  R. Koppensteiner,et al.  Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes , 2020, Cardiovascular Drugs and Therapy.

[8]  M. Alessi,et al.  Epinephrine restores platelet functions inhibited by ticagrelor: A mechanistic approach. , 2019, European journal of pharmacology.

[9]  M. Heikenwalder,et al.  Platelets in chronic liver disease, from bench to bedside , 2019, JHEP reports.

[10]  C. Strassburg,et al.  Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS , 2019, Gut.

[11]  C. Nielsen,et al.  Reduced platelet activation and platelet aggregation in patients with alcoholic liver cirrhosis , 2018, Platelets.

[12]  Deepak L. Bhatt,et al.  Novel aspects of antiplatelet therapy in cardiovascular disease , 2018, Research and practice in thrombosis and haemostasis.

[13]  A. Michelson,et al.  Platelet Function in Thrombocytopenic Patients with Chronic Liver Disease , 2017 .

[14]  M. Peck‐Radosavljevic.  Thrombocytopenia in chronic liver disease , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[15]  S. Basili,et al.  Low‐grade endotoxemia and platelet activation in cirrhosis , 2017, Hepatology.

[16]  A. Michelson,et al.  Platelet Physiology , 2016, Seminars in Thrombosis and Hemostasis.

[17]  M. Nybo,et al.  An overview of platelet indices and methods for evaluating platelet function in thrombocytopenic patients , 2014, European journal of haematology.

[18]  P. Mannucci,et al.  The coagulopathy of chronic liver disease. , 2011, The New England journal of medicine.

[19]  F. Nevens,et al.  Review article: blood platelet number and function in chronic liver disease and cirrhosis , 2008, Alimentary pharmacology & therapeutics.

[20]  Pere Ginès1.  Complications of Cirrhosis , 2008, Seminars in liver disease.

[21]  U. Kalina,et al.  Antithrombin significantly influences platelet adhesion onto immobilized fibrinogen in an in-vitro system simulating low flow , 2006, Thrombosis journal.

[22]  P. D. de Groot,et al.  Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity , 2006, Hepatology.

[23]  A. Panasiuk,et al.  Blood platelet and monocyte activations and relation to stages of liver cirrhosis. , 2005, World journal of gastroenterology.

[24]  H. Fusegawa,et al.  Platelet activation in patients with alcoholic liver disease. , 2005, The Tokai journal of experimental and clinical medicine.

[25]  A. Michelson.  How Platelets Work: Platelet Function and Dysfunction , 2003, Journal of Thrombosis and Thrombolysis.

[26]  J. Osada,et al.  Activation of blood platelets in chronic hepatitis and liver cirrhosis P-selectin expression on blood platelets and secretory activity of beta-thromboglobulin and platelet factor-4. , 2001, Hepato-gastroenterology.

[27]  K Fujikawa,et al.  Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Escolar,et al.  Existence of a platelet‐adhesion defect in patients with cirrhosis independent of hematocrit: Studies under flow conditions , 1996, Hepatology.

[29]  A. Michelson.  Flow cytometry: a clinical test of platelet function. , 1996, Blood.

[30]  R. Caporale,et al.  Defective aggregation in cirrhosis is independent of in vivo platelet activation. , 1996, Journal of hepatology.

[31]  E. Cecchi,et al.  Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. , 1993, Gastroenterology.

[32]  P. Romagnoli,et al.  Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. , 1992, Gastroenterology.

[33]  M. Ruggiero,et al.  Altered platelet function in cirrhosis of the liver: Impairment of inositol lipid and arachidonic acid metabolism in response to agonists , 1988, Hepatology.

[34]  F. Cominelli,et al.  Molecular mechanism underlying impaired platelet responsiveness in liver cirrhosis , 1987, FEBS letters.

[35]  Deepak L. Bhatt,et al.  Laboratory Monitoring of Antiplatelet Therapy , 2019, Platelets.

[36]  A. Kauskot,et al.  Platelet Receptors , 2019, Platelets.

[37]  G. Escolar,et al.  Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100 ): influence of hematocrit elevation. , 1999, Haematologica.

[38]  R. Colman,et al.  Differential requirements for platelet aggregation and inhibition of adenylate cyclase by epinephrine. Studies of a familial platelet alpha 2-adrenergic receptor defect. , 1988, Blood.